Zhitong Finance App News, Shiyao Group (01093.HK) issued an announcement stating that the relevant group signed a strategic cooperation and licensing agreement with AstraZeneca to develop innovative long-term peptide drugs using the Group's long-term delivery technology platform and peptide drug AI discovery platform. The Board is pleased to announce that the Group has received a $25 million R&D milestone payment from AstraZeneca on July 10, 2026, following the previous receipt of the down payment under the agreement on May 29, 2026. The achievement of this milestone indicates that related R&D work under the agreement is progressing steadily according to the plan.

Zhitong Finance App News, Shiyao Group (01093.HK) issued an announcement stating that the relevant group signed a strategic cooperation and licensing agreement with AstraZeneca to develop innovative long-term peptide drugs using the Group's long-term delivery technology platform and peptide drug AI discovery platform. The Board is pleased to announce that the Group has received a $25 million R&D milestone payment from AstraZeneca on July 10, 2026, following the previous receipt of the down payment under the agreement on May 29, 2026. The achievement of this milestone indicates that related R&D work under the agreement is progressing steadily according to the plan.